Restore Vision Raises ¥1.3B for Gene Therapy in Eye Diseases

Tokyo-based Restore Vision has successfully secured ¥1.3 billion in a pre-Series B funding round, propelling its mission to develop groundbreaking gene therapies for degenerative retinal conditions. This significant capital infusion underscores growing investor confidence in the company's innovative approach to restoring sight.

The financing round saw robust participation from a consortium of established and new investors. Existing backers demonstrating continued support include Higo Bank Capital, Kyoto University Innovation Capital, JIC Venture Growth Investments, the Japan Science and Technology Agency, and Remiges Ventures. New strategic partners joining the venture are Astellas Venture Management, Ajinomoto, Shionogi & Co., Ltd., and Japan Venture Capital, signaling broad industry endorsement.

At the heart of Restore Vision's pipeline is its lead candidate, RV-001. This novel gene therapy utilizes an adeno-associated virus (AAV) vector to deliver a proprietary light-sensor protein, dubbed "Chimera Rhodopsin," directly into retinal interneurons via intravitreal injection. This optogenetics-based strategy aims to regenerate vision in patients suffering from conditions like retinitis pigmentosa, where photoreceptor cells have been lost. The company highlights that this represents the world's first clinical trial employing optogenetics gene therapy with Chimera Rhodopsin, marking a significant milestone in the field.

The company has already achieved a critical development step, with the first patient having received administration of RV-001 in a Phase I/II clinical trial conducted at Keio University Hospital. This successful patient dosing paves the way for further clinical evaluation and validation of the therapy's safety and efficacy.

With this latest funding, Restore Vision's total equity raised now stands at approximately ¥3.5 billion. This builds upon previous financing rounds, including a seed round of ¥300 million, a Pre-Series A of ¥210 million, and a Series A round totaling ¥1.66 billion. Furthermore, the company has benefited from substantial non-dilutive funding, receiving approximately ¥2.1 billion through AMED's "Drug Discovery Venture Ecosystem Enhancement Project," with potential for an additional ¥4.5 billion in future tranches. This brings the total funding, including grants, to an impressive ¥5.8 billion.

The newly acquired capital will be strategically deployed to advance the global clinical development of RV-001, support ongoing research and development for a second pipeline asset, bolster management infrastructure, and expand the company's scientific and operational teams. Restore Vision is committed to accelerating the international clinical trials for RV-001, aiming to bring this potentially transformative therapy to patients worldwide.

The gene therapy market, particularly for rare diseases and unmet medical needs like inherited retinal dystrophies, is experiencing substantial growth, driven by advancements in genetic engineering and increasing therapeutic applications. Restore Vision's progress positions it to capture a significant share of this expanding sector, offering hope for millions affected by vision loss.